Total Payments
$1.0M
2024 Payments
$41,930
Companies
37
Transactions
922
Medicare Patients
3,356
Medicare Billing
$8.8M
Payment Breakdown by Category
Other$568,667 (56.6%)
Consulting$320,807 (31.9%)
Travel$90,064 (9.0%)
Food & Beverage$16,066 (1.6%)
Research$9,304 (0.9%)
Education$149.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $568,667 | 207 | 56.6% |
| Consulting Fee | $320,807 | 78 | 31.9% |
| Travel and Lodging | $90,064 | 269 | 9.0% |
| Food and Beverage | $16,066 | 362 | 1.6% |
| Unspecified | $9,304 | 3 | 0.9% |
| Education | $149.85 | 3 | 0.0% |
Payments by Type
General
$995,753
919 transactions
Research
$9,304
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $288,875 | 268 | $0 (2022) |
| Biogen, Inc. | $215,596 | 207 | $0 (2024) |
| Genentech USA, Inc. | $175,929 | 116 | $0 (2024) |
| Celgene Corporation | $92,910 | 70 | $0 (2024) |
| EMD Serono, Inc. | $72,051 | 83 | $0 (2023) |
| TG Therapeutics, Inc. | $51,792 | 36 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $39,687 | 52 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $14,015 | 11 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $13,167 | 13 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $12,943 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,930 | 36 | TG Therapeutics, Inc. ($29,296) |
| 2023 | $86,167 | 85 | Biogen, Inc. ($36,941) |
| 2022 | $52,295 | 42 | Genentech USA, Inc. ($19,780) |
| 2021 | $47,644 | 40 | Biogen, Inc. ($13,160) |
| 2020 | $61,497 | 55 | Celgene Corporation ($16,443) |
| 2019 | $165,615 | 152 | Genentech USA, Inc. ($50,161) |
| 2018 | $220,805 | 198 | GENZYME CORPORATION ($81,919) |
| 2017 | $329,105 | 314 | GENZYME CORPORATION ($168,039) |
All Payment Transactions
922 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/02/2024 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,614.00 | General |
| 11/28/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: BIOLOGIC | ||||||
| 11/15/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.50 | General |
| Category: NEUROLOGY | ||||||
| 11/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 10/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 10/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $275.29 | General |
| Category: Immunology | ||||||
| 10/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Immunology | ||||||
| 10/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $25.36 | General |
| Category: Immunology | ||||||
| 10/14/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 09/26/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | Cash or cash equivalent | $119.34 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Travel and Lodging | Cash or cash equivalent | $58.29 | General |
| Category: Immunology | ||||||
| 09/24/2024 | Cycle Pharmaceuticals Inc | Tascenso ODT (Drug) | Food and Beverage | In-kind items and services | $45.47 | General |
| Category: NEUROLOGY | ||||||
| 09/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $119.00 | General |
| Category: Immunology | ||||||
| 09/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $76.47 | General |
| Category: Immunology | ||||||
| 08/10/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 08/10/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Immunology | ||||||
| 08/10/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $18.67 | General |
| Category: Immunology | ||||||
| 08/01/2024 | Mylan Specialty L.P. | GLATIRAMER ACETATE (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Immunomodulators | ||||||
| 06/28/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 06/14/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Dry eyes | ||||||
| 06/05/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Genetic Disease | ||||||
| 05/23/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 05/21/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase IIIb, Multicenter, randomized, parallel-group, open-label study to evaluate the effects of ocrelizumab on immune responses in patients with Relapsing forms of multiple sclerosis | F. Hoffmann-La Roche AG | $4,617 | 1 |
| Publication support research related | Novartis Pharma AG | $3,164 | 1 |
| RPC01-201 - A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of | Celgene Corporation | $1,524 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 737 | 31,164 | $4.4M | $1.3M |
| 2022 | 16 | 679 | 73,757 | $7.7M | $2.2M |
| 2021 | 18 | 963 | 78,653 | $9.0M | $2.3M |
| 2020 | 17 | 977 | 98,499 | $11.8M | $3.0M |
Total Patients
3,356
Total Services
282,073
Medicare Billing
$8.8M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 26 | 18,300 | $2.7M | $836,732 | 30.5% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 19 | 5,020 | $702,800 | $179,678 | 25.6% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 15 | 5,490 | $686,250 | $176,315 | 25.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 1,080 | $69,120 | $20,235 | 29.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 112 | 159 | $81,258 | $19,720 | 24.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 53 | 176 | $32,736 | $9,006 | 27.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 47 | 76 | $28,500 | $7,650 | 26.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 39 | 202 | $11,918 | $3,281 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 31 | $11,222 | $2,834 | 25.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $9,435 | $2,181 | 23.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 58 | 127 | $5,588 | $1,509 | 27.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 32 | 57 | $4,617 | $1,165 | 25.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 42 | 99 | $3,960 | $1,088 | 27.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 99 | 134 | $1,608 | $1,084 | 67.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 17 | $4,369 | $1,013 | 23.2% |
| 92133 | Imaging of optic nerve | Office | 2023 | 35 | 35 | $3,583 | $936.18 | 26.1% |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | Office | 2023 | 19 | 52 | $2,288 | $706.90 | 30.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 12 | 14 | $1,680 | $333.56 | 19.9% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 34 | 52 | $936.00 | $223.43 | 23.9% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 16 | 28 | $364.00 | $86.05 | 23.6% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2022 | 48 | 37,800 | $6.1M | $1.7M | 27.5% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2022 | 12 | 18,600 | $815,052 | $346,668 | 42.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 19 | 16,400 | $213,200 | $78,581 | 36.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 140 | 198 | $107,038 | $24,787 | 23.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 58 | 88 | $52,800 | $9,603 | 18.2% |
About Dr. Jonathan Calkwood, M.D
Dr. Jonathan Calkwood, M.D is a Neurology healthcare provider based in Golden Valley, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194765388.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Calkwood, M.D has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $41,930 received in 2024. These payments were reported across 922 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($568,667).
As a Medicare-enrolled provider, Calkwood has provided services to 3,356 Medicare beneficiaries, totaling 282,073 services with total Medicare billing of $8.8M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Golden Valley, MN
- Active Since 06/07/2006
- Last Updated 05/17/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1194765388
Products in Payments
- LEMTRADA (Drug) $183,667
- OCREVUS (Biological) $116,418
- TYSABRI (Biological) $80,426
- AUBAGIO (Drug) $77,984
- Ozanimod (Drug) $50,572
- BRIUMVI (Drug) $43,664
- TECFIDERA (Drug) $41,325
- Ocrevus (Biological) $33,963
- ZEPOSIA (Drug) $30,444
- Non-Covered Product (Drug) $29,551
- GILENYA (Drug) $23,780
- DISEASE STATE (Drug) $21,554
- Mavenclad (Biological) $21,343
- Mavenclad (Drug) $17,524
- Rebif (Biological) $16,423
- COPAXONE (Drug) $14,015
- Betaseron (Drug) $13,167
- MAVENCLAD (Drug) $11,512
- MAYZENT (Drug) $10,859
- AMPYRA (Drug) $5,903
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Golden Valley
Jessica Stulc, Md, MD
Neurology — Payments: $339,019
Neurology $339,019
Dr. Irfan Altafullah, M.b., B.s, M.B., B.S
Neurology — Payments: $203,754
Neurology $203,754
Dr. Jessica Heiring
Neurology — Payments: $194,211
Neurology $194,211
Dr. Joanne Rogin, M.d, M.D
Neurology — Payments: $120,981
Neurology $120,981
Dr. Randall Schapiro, M.d, M.D
Neurology — Payments: $67,098
Neurology $67,098
Praful Kelkar, M.d, M.D
Neurology — Payments: $44,390
Neurology $44,390